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Abstract
Background: Estimates of cancer prevalence are widely based on limited duration, often including patients living
after a cancer diagnosis made in the previous 5 years and less frequently on complete prevalence (i.e., including all
patients regardless of the time elapsed since diagnosis). This study aims to provide estimates of complete cancer
prevalence in Italy by sex, age, and time since diagnosis for all cancers combined, and for selected cancer types.
Projections were made up to 2020, overall and by time since diagnosis.
Methods: Data were from 27 Italian population-based cancer registries, covering 32% of the Italian population, able
to provide at least 7 years of registration as of December 2009 and follow-up of vital status as of December 2013.
The data were used to compute the limited-duration prevalence, in order to estimate the complete prevalence by
means of the COMPREV software.
Results: In 2010, 2,637,975 persons were estimated to live in Italy after a cancer diagnosis, 1.2 million men and 1.4
million women, or 4.6% of the Italian population. A quarter of male prevalent cases had prostate cancer (n = 305,044),
while 42% of prevalent women had breast cancer (n = 604,841). More than 1.5 million people (2.7% of Italians) were
alive since 5 or more years after diagnosis and 20% since ≥15 years. It is projected that, in 2020 in Italy, there will be 3.6
million prevalent cancer cases (+ 37% vs 2010). The largest 10-year increases are foreseen for prostate (+ 85%) and for
thyroid cancers (+ 79%), and for long-term survivors diagnosed since 20 or more years (+ 45%). Among the population
aged ≥75 years, 22% will have had a previous cancer diagnosis.
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Conclusions: The number of persons living after a cancer diagnosis is estimated to rise of approximately 3% per year
in Italy. The availability of detailed estimates and projections of the complete prevalence are intended to help the
implementation of guidelines aimed to enhance the long-term follow-up of cancer survivors and to contribute their
rehabilitation needs.
Keywords: Cancer prevalence, Projections, Survivors, Italy
Background
Estimates of cancer prevalence are widely based on lim-
ited duration prevalence, including only patients living
after a cancer diagnosis made in the previous 5 years
[1, 2]. Prevalence, regardless of the time since diagnosis
(i.e., complete prevalence), is less frequently estimated
than limited duration prevalence [3–9]. Overall age-
standardized cancer incidence and mortality rates have
declined over the past 10 years in the majority of high
income countries, whereas the complete prevalence has
been consistently increasing in the early 2000s [3, 4, 6,
8, 10, 11]. Complete prevalence is generally measured
in absolute numbers and proportions, i.e., not age-
standardized. Thus, improved survival [12, 13] and
population ageing (increasing absolute number of new
cancer diagnoses) imply a progressive increase in
tumour prevalence.
Cancer prevalence includes patients currently treated
for cancer; those who have become cancer free, but still
have a measurable excess risk of recurrence or death;
and, finally, patients having death rates similar to those
of the general population who can be considered “cured
patients” [14]. Many of these individuals are possibly af-
fected by physical, cognitive, and/or psychosocial limita-
tions [15].
The aim of this study was to provide a description of
the number of people living in Italy at January 1, 2010
after a cancer diagnosis, for all cancers combined and
for a selection of cancer types by sex, age, and time since
diagnosis. In addition, projections of cancer prevalence
in Italy are presented up to the year 2020. Estimates and
projections of complete tumour prevalence and charac-
teristics of prevalent patients are necessary to help clini-
cians and health care planners in improving long-term
care of patients and in allocating appropriately health
care resources. Moreover, they may provide helpful
information to a growing number of cancer patients or
former patients.
Methods
Study design and data sources
This is a descriptive analysis of individual data col-
lected during the period 1976-2009 from 27
population-based Italian cancer registries (i.e., 32%
of the entire Italian population in 2010), which
agreed to participate in the study and were able to
provide at least 7 years of cancer registration as of
December 31, 2009 (Appendix 1) and follow-up of
vital status as of December 31, 2013. The Italian le-
gislation identifies Cancer Registries as collectors of
personal data for surveillance purposes without ex-
plicit individual consent. The approval of a research
ethic committee is not required, since this descrip-
tive study was conducted without any direct or in-
direct intervention on patients.
Prevalence for all malignant tumours (ICD-10: C00-
C43, C45-C96) and 34 cancer types or their combina-
tions were estimated and presented in this study for all
age groups. Urinary bladder cancers with benign or un-
certain behaviour, and in situ tumours were also in-
cluded. Only non melanoma skin cancers (ICD-10 C44)
were excluded. ICD-O-3 morphology codes were used to
define specific subtypes.
Statistical methods
The clinical and demographic characteristics of the
persons registered with a diagnosis of cancers in the
Italian CRs were used to estimate: 1) how many of
them were still alive at January 1, 2010 regardless
of time since diagnosis -i.e., complete prevalence
count- by cancer type, sex, and age group; 2) the
prevalence proportion in Italy at 2010 for each can-
cer type, by sex, and age; 3) the complete prevalence
(count and proportion) at 1st January 2015 and
2020, overall and by time since diagnosis; and 4) de-
scribe the changing over time of these estimates.
For each cancer registry we computed the limited
duration prevalence, i.e. the number of patients diag-
nosed in the period of the registration activity (be-
tween 7 and 34 years) at January 1, 2010, using the
counting method implemented in SEER*Stat software
[16]. This maximum limited duration prevalence was
corrected, using the COMPREV software [17], by
means of completeness index [18, 19], to estimate
the total number of cancer patients alive, regardless
of when they were diagnosed. Completeness indices
were estimated by cancer type, sex, age, and time
since diagnosis. Prevalence was computed as an ab-
solute number, as well as a proportion per 100,000
residents people by cancer type, sex, age group, area
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of residence, and years since diagnosis. Patients with
more than one primary cancer were included in the
computation of prevalence for each cancer type or
combination. In the analyses for all types combined,
only the first cancer was considered. Completeness
indices were obtained by statistical regression models
of incidence and survival using data from 8 long-term
registries (Appendix 1) with an available observation
period of at least 18 years before 2010 [20, 21]. Rela-
tive survival and incidence functions were estimated
by means of parametric models within the period
1985-2011 for survival and 1985-2009 for incidence.
The survival model was a parametric cure model as-
suming that a proportion of individuals with cancer
were bound to die (fatal cases) with a survival follow-
ing a Weibull distribution, while the remaining pro-
portion (cured fraction) had the same mortality rate
as that of the general population with the same age
and gender stratification [14, 20]. The parameters of
the survival model were estimated by cancer type,
sex, and age class (0-14, 15-44, 45-54, 55-64, 65-74,
75+ years) through the SAS procedure NLIN. A
period effect was included on the hazard of dying of
cancer. Incidence data were categorised according to
cancer type, sex, five-year age group, and birth cohort
(< 1899, 1900-1904,…, 2005-2009). A sixth degree
polynomial age-cohort model of crude incidence rates
was fitted through the SAS LOGISTIC procedure for
each cancer type and sex [21].
Complete prevalence proportions were projected to
2020 by cancer type, sex, age, and registry, assuming
that complete prevalence will follow a linear func-
tion, based on the trend of the last three calendar
years (i.e., 2007-2009). This simplified assumption
(linear and constant trend) may not be valid for
long-term projections, but it is reasonable for short
or medium-term (e.g., 10-year) ones. Other assump-
tions (e.g., log-linear models) were explored [4, 6],
showing consistent results for common cancer types,
but unstable projections for the rarest.
The absolute number of prevalent cases in Italy
was obtained using proportions of prevalence esti-
mates (age-, sex-, and cancer type-specific) from CRs
included in this study, multiplied by the Italian na-
tional population by sex and age observed at January
1, 2010. Proportions projected to 2020 were thus
multiplied to Italian population forecasted at January
1, 2020 [22].
Results
Prevalence estimates at 2010
In Italy in 2010, 2,637,975 persons were alive after a cancer
diagnosis, corresponding to 4.6% of all the Italian popula-
tion (Appendix 2). Prevalence proportions increase with
age: 3.1% at age 45-54 years, 6.6% at 55-64 years,
12.1% at 65-74 years, and nearly 17% after age 75 years
(Appendix 2) with differences by sex (Tables 1 and 2).
Men living in Italy after a cancer diagnosis in 2010
were 1,194,033, corresponding to 4.3% (4250/
100,000) of all Italian male population (Table 1).
This proportion increased from less than 1% below
the age of 45 years, to > 20% for men aged ≥75 years.
The most frequent tumours in terms of prevalence
were prostate (305,044 of prevalent cases at January,
1st 2010) representing 25.5% of all cases or 1.1% of
all Italian men, followed by bladder (192,611 men,
16.1%) and colorectal (185,532 men, 15.5%) tumours.
Italian women living after a cancer diagnosis were
1,443,942 (Table 2), corresponding to 4.8% of all Ital-
ian women. Breast cancer represented 41.9% of all
cancers (604,841), followed by colorectal cancers
(171,847, 11.9% of all female prevalent cases, 0.6% of
all Italian women) and by endometrial cancers
(103,321, 7.2% and 0.3%, respectively). Notably, the
fourth most frequent cancer type diagnosed in Italian
prevalent women is thyroid (93,341 women, 6.5% of
all female prevalent cases). Prevalent women were
younger than men. Women aged 15-44 years living
after a diagnosis represented 1% of the whole Italian
population, they were 4% at ages 45-54 years, 7% at
ages 55-64 years, 11% at ages 65-74 years, and 14%
for women aged ≥75 years (Table 2).
More than 1.5 million people (i.e., 2.7% of all Italian
residents) were alive after ≥5 years since diagnosis. They
were 60% of all prevalent cases, 64% of women and 55%
of men. The distribution of prevalent cases by time since
diagnosis depends on cancer type (Fig. 1). The percent-
age of prevalent cases diagnosed since less than 2 years
varied from 39% for lung cancer patients to 15% for
female breast and 7% for cervical cancer patients. Con-
versely, the percentage of prevalent cases diagnosed
≥15 years before was 59% for cervical cancer, 35% for
stomach cancer and 31% for endometrial cancer, but
only 4% for prostate and 13% for lung cancer patients.
Notably, patients diagnosed ≥15 years before were
21% of all prevalent cases (16% among men and 25%
among women).
Prevalence projections for 2020
In 2020, there will be 3.6 million prevalent cancer cases in
Italy (Table 3), 1.9 million women and 1.7 million men,
with a 10-year increase of 37% (41 and 33% in men and
women, respectively). In 2020, 2.6% of all Italian women
(0.8 millions) will be alive after a breast cancer diagnosis
and more than half a million patients (2.1% of all men) will
be alive after a prostate cancer diagnosis (Table 3). The lar-
gest 10-year increases are foreseen for prostate (+ 85%) and
for thyroid cancers (+ 79%, 212,863 cases), which will
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Fig. 1 Complete prevalence by time since diagnosis for selected cancer types* in Italy at January 1, 2010. *Cancer types diagnosed in > 50,000
persons, sorted by number of cases
Table 3 Projected complete prevalence (cases) at January 1, 2020 by sex and 10-year variations in Italy
Prevalent cases Variation (%)
2020 10-year period
Cancer Typea Men Women Total Men Women Total
All types but skin non-melanoma 1687,049 1,922,086 3,609,135 41.3% 33.1% 36.8%
Upper aero-digestive tract 36,081 21,831 57,911 34.9% 41.5% 37.3%
Stomach 50,327 32,033 82,360 9.5% −9.9% 1.0%
Colon, Rectum, Anus 280,277 233,245 513,522 51.1% 35.7% 43.7%
Liver 25,234 8531 33,765 44.6% 16.4% 36.2%
Larynx 47,015 6006 53,020 4.9% 36.3% 7.7%
Lung 77,159 40,657 117,816 22.4% 71.4% 35.8%
Skin Melanoma 80,069 89,831 169,900 78.0% 56.2% 65.8%
Connective Tissue 17,040 11,815 28,855 44.9% 19.1% 33.1%
Female Breast 834,154 834,154 37.9% 37.9%
Cervix Uteri 51,136 51,136 −13.2% −13.2%
Corpus Uteri (endometrium) 122,553 122,553 18.6% 18.6%
Ovary 49,807 49,807 9.2% 9.2%
Prostate 563,960 563,960 84.9% 84.9%
Testis 63,395 63,395 67.1% 67.1%
Kidney 97,249 47,151 144,400 54.8% 33.8% 47.2%
Bladder 255,015 58,608 313,624 32.4% 22.6% 30.4%
Brain and central nervous system 23,505 29,314 52,819 45.9% 26.7% 34.6%
Thyroid 45,949 166,914 212,863 80.1% 78.8% 79.1%
Hodgkin Lymphoma 37,692 29,314 67,006 35.5% 43.5% 38.9%
Non- Hodgkin Lymphoma 82,780 73,584 156,364 45.7% 36.5% 41.2%
Leukaemias 45,880 39,100 84,980 27.1% 25.3% 26.3%
Multiple Myeloma 19,472 17,159 36,631 52.3% 39.8% 46.1%
a Cancer types with more than 20,000 prevalent cases at 2010
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become the third most frequent prevalent cancer types
among Italian women. A more than 50% increases are also
expected in 2020 for prevalence after diagnosis of testicular
cancer (63,395 patients) or skin melanoma (169,900). A
limited change in prevalence (variations < 10%) is expected
for ovary, larynx, and stomach, with cervical cancer being
the only cancer type showing a decline in prevalence (−
13%) (Table 3).
Nearly 22% (21,657/100,000) of population aged
≥75 years in 2020 will have had a previous cancer
diagnosis (Table 4). Below 45 years of age, prevalent
cases will be 228,145 (i.e., 0.8% of all cases, 726/
100,000) and, in both sexes, the most frequent cancer
type will be thyroid cancer, experienced by 31,971
women and 9141 men.
Prevalent cases diagnosed within 2 years were the
only group showing a negligible increase from 2010
to 2020 (+ 3% in the examined period), while a 19%
increase was observed for cases diagnosed between 2
and 5 years before, 30-34% for cases diagnosed be-
tween 5 and 20 years earlier, and 45% increased for
long-term survivors diagnosed ≥20 years before
(Fig. 2).
Discussion
In 2010, 2.6 million people were living in Italy after
a cancer diagnosis and this number will reach 3.6
million in 2020, increasing from 4.6% to 5.7% (i.e.,
one out of 17 Italians) of the overall population. The
estimated overall trend in the present decade in Italy
(+ 3.2% per year) is comparable to that estimated in
the same period in the USA (+ 2.8% per year) [5],
UK (+ 3.3%) [4], and Switzerland (+ 2.5%) [6].
Table 4 Projected complete prevalence at January 1, 2020 by sex and age groups in Italy a
SEX, Cancer type Prevalent cases Prevalence proportion per 100,000
All ages % 00-44 45-74 75+ All ages 00-44 45-74 75+
MEN and WOMEN
All types but skin non-melanoma 3,609,135 100.0% 228,145 1,897,543 1,483,448 5731 726 16,383 21,657
Colon, rectum, anus 513,522 14.2% 4954 231,800 276,767 808 15 2080 3952
Skin melanoma 169,900 4.7% 24,038 101,180 44,682 271 76 857 673
Female breast 834,154 23.1% 29,758 498,614 305,781 2622 201 8215 7297
Corpus uteri (endometrium) 122,553 3.4% 1707 65,765 55,081 379 10 1104 1269
Prostate 563,960 15.6% 1174 255,514 307,272 2056 12 5634 12,343
Bladder 313,624 8.7% 4130 128,332 181,162 563 15 1323 2836
Thyroid 212,863 5.9% 41,112 145,562 26,189 309 127 1084 379
Non-Hodgkin lymphoma 156,364 4.3% 14,948 87,255 54,161 247 47 739 789
MEN
All types but skin non-melanoma 1687,049 100% 95,056 834,967 757,026 5444 615 15,678 28,728
Colon, rectum, anus 280,277 16.6% 2250 135,206 142,821 902 13 2573 5267
Skin melanoma 80,069 4.7% 8760 50,437 20,872 256 57 898 815
Prostate 563,960 33.4% 1174 255,514 307,272 2056 12 5634 12,343
Bladder 255,015 15.1% 2636 106,086 146,294 958 20 2323 5932
Thyroid 45,949 2.7% 9141 31,444 5364 142 59 490 209
Non-Hodgkin lymphoma 82,780 4.9% 8959 49,513 24,309 271 58 871 946
WOMEN
All types but skin non-melanoma 1,922,086 100% 133,089 1,062,575 726,422 5992 888 17,374 17,007
Colon, rectum, anus 233,245 12.1% 2704 96,594 133,947 720 17 1633 3105
Skin melanoma 89,831 4.7% 15,278 50,742 23,811 284 102 822 581
Breast 834,154 43.4% 29,758 498,614 305,781 2622 201 8215 7297
Corpus uteri (endometrium) 122,553 6.4% 1707 65,765 55,081 379 10 1104 1269
Bladder 58,608 3.0% 1494 22,246 34,868 195 10 405 859
Thyroid 166,914 8.7% 31,971 114,119 20,825 508 218 1761 516
Non-Hodgkin lymphoma 73,584 3.8% 5989 37,743 29,852 225 37 618 688
a Most frequent cancer types are shown: Cancer types or combinations with > 100,000 prevalent cases
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The expected 37% increase in the present decade
in Italy will be more marked (i.e., nearly + 50%)
among long-term survivors diagnosed ≥20 years be-
fore; they will be more than half a million in Italy
(519,356), 14% of all prevalent cases (11% in men
and 18% in women). Most of them can be considered
as cured since they had already reached a similar life
expectancy (i.e., death rates) of the corresponding
general population [14].
A higher proportion of women (55%) than that of
men emerged among prevalent cancer cases at 2010
in the present Italian study, in agreement with find-
ings from most studies conducted in other countries
[4–6, 9] but France (where 53% were men, 6.4% of
the French population) [8]. In Italy, female breast
cancer cases represented 23% of all prevalent cases,
and affected the distribution of cancer prevalence by
age. The thyroid cancer epidemic in Italy also con-
tributed to an excess in females, below age 45 years
thyroid cancer was the most frequent prevalent type
in 2010 (29,340 men and women), and this number
will substantially increase to more than 41,000 in
2020. It should be noted, however, that a large pro-
portion of thyroid cancer incidence and prevalence
may be affected by overdiagnosis; i.e., the detection
of cancer cases that would not otherwise result in
causing symptoms or deaths [23, 24].
An important role on variation of cancer preva-
lence is played by screening programmes, inducing a
reduction of cervical and colorectal prevalent cancers
cases, while early detection of breast and prostate
cancers may inflate number of prevalent cases [25].
In particular, screening can prevent cervical cancer,
with a consequent major effect on prevalence reduc-
tion, i.e., − 13% in 10 years in the present study.
Distribution of cancer prevalence by age is also
noteworthy. In 2010, 37% of prevalent patients were
75 years or older (38% in men, 35% in women). In
this age group, they will reach 41% in 2020, with
more than 20% of men and 14% of women will have
experienced a previous cancer diagnosis. These pro-
portions were similar to those reported by other
studies, showing also that elderly cancer patients had
more severe comorbidity conditions than non cancer
patients [26].
At the opposite end of the age spectrum, 8% of
Italian prevalent cases were younger than 44 years of
age and 10% were aged 45–54 years. It has been re-
cently estimated that 44,135 persons living in Italy
in 2010 had had a cancer diagnosis during childhood
[27]; they represented 0.07% of the Italian population
and 1.7% of prevalent cases diagnosed at any age. In
similar studies conducted in the USA [28], a sub-
stantial proportion of morbidities emerged in child-
hood cancer patients several years after diagnosis,
and there is growing awareness on potentially long-
term risks affecting the survivors’ future physical,
cognitive, and/or psychosocial health [29]. The im-
pact of a cancer diagnosis is rather different between
younger and older survivors, the first facing more
pronounced socio-economic consequences [30, 31],
as well as psychosocial impairments in fertility and
sexuality [32, 33].
We acknowledge the several limitations of our ana-
lyses. First, data from Italian cancer registries (AIR-
TUM) included one third of the Italian population in
2010 and the representativeness for the national
prevalence estimates may be questionable [34]. To
overcome this issue, we adjusted estimated propor-
tions in cancer registry areas for the age distribution
of the whole Italian population. Moreover, since can-
cer registries have been active in Italy from a rela-
tively recent time period, the complete prevalence has
been estimated through statistical models. Notably,
the validation of complete prevalence estimation by
means of COMPREV method in Italy and elsewhere
[19] is reasonably reassuring. In particular, the valid-
ation of COMPREV method shows negligible (i.e., <
5%) differences, when comparing observed prevalence
for cancer registries with ≥30 years of observation
and estimated prevalence using complete indexes ap-
plied to the same registries and truncated data [21,
page 34].
On the other hand, the strengths of this
population-based study are represented by the size of
the study population, which included nearly 1.7 mil-
lion incident cancer cases, and its long-term follow-
up, more than a half of these cases were followed-up
for > 20 years post diagnosis. In addition, data and
period used were updated in the present study (see
Appendix 1), including an additional number of years
Fig. 2 Complete cancer prevalence (proportions) in Italy from
2006 to 2020 by years since diagnosis. *Data for 2006 obtained
from ref. 21. Filled symbols (e.g., •) represent estimated values,
empty symbols (e.g., ο) represent projected values
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of observation and follow-up, in comparison with pre-
vious studies on the same topic [21].
The accuracy of future projections of prevalence is
necessarily uncertain and lies on statistical models
based on assumptions reflecting unknown evolution
of incidence, survival, and demographic changes.
This may also affect comparisons with trends re-
ported in other countries, obtained using different
assumptions and statistical models [4, 6, 26]. In our
medium-term projections, the hypothesis that
complete prevalence at 2020 can be predicted by a
linear function of calendar year as regressor variable
is supported by empirical evidence, at least for all
cancer types combined and for most frequent cancer
types, consistently showing an approximate linear
trend in recent years [5, 21]. Notably, the use of a
longer period (5 calendar years) to estimate linear
slope did not materially modify the estimates.
Detailed estimates and projections of numbers of
persons living after different cancer diagnoses are
particularly relevant for policy makers to better plan
health care resource allocation and meet cancer pa-
tients needs, including not only initial treatment, but
also rehabilitation and long-term surveillance. How-
ever, to date, guidelines pertaining to survivorship
care have been largely based on consensus rather
than on empirical evidence [35–37].
In the USA, the main driver of cancer costs growth is
population ageing, with an overall increase of 27% by
the year 2020 from 2010 levels [38]. The largest increase
in expenditures is attributable to the continuing phase of
care (i.e., > 1-year post-diagnosis and > 1 year from
death) for prostate and female breast cancer, with 42
and 32% increase respectively [38]. Although health care
costs in the continuing phase of care is lower than in
the first course of treatment (first year since diagnosis)
and in the last year of life, the large number of survi-
vors in the continuing phase of care is driving most
of healthcare resources. Similar findings, on the
distribution of cancer burden by phase of care, are
expected in Italy [39].
Conclusions
The availability of reliable and accurate estimates of
complete prevalence and predictions of the rising
tide of people living after cancer diagnosis may be
helpful not only to epidemiologists and health-care
planners, but also to clinicians in developing
guidelines to enhance and standardize the long-term
follow-up of cancer survivors. Furthermore, these
estimates are intended for patients to help
recovering social activities and supporting rehabilita-
tion demands.
Appendix 1
Population and incident cases in Italian cancer registries
with ≥7 years of registration in period 1976-2009
CANCER
REGISTRY
Period of
activity
Population
at January
1st 2010
Incident
cases up
to 2009a
Period
of registration
Years
included
to 2009
(per 1000)
Alto
Adige - Sudtirol
1995–2010 15 494 37,119
Biella 1995–2010 15 185 20,362
Catania-
Messina
2003–2011 7 1727 58,753
Catanzaro 2003–2009 7 230 7755
Como 2003–2011 7 577 24,963
Ferrarab 1991–2011 19 354 50,925
Friuli
Venezia
Giulia
1995–2010 15 1219 128,738
Genovab 1986–2009 24 592 112,812
Latina 1996–2011 14 531 32,330
Mantova 1999–2010 11 404 27,541
Milano 1999–2010 11 1215 103,283
Modenab 1988–2011 22 676 84,155
Napoli 1996–2011 14 561 28,250
Nuoro 2003–2011 7 219 7889
Palermo 2003–2011 7 1239 40,926
Parmab 1978–2011 32 420 80,744
Ragusab 1981–2011 29 303 31,283
Reggio
Emilia
1996–2011 14 508 41,379
Romagna 1993–2011 17 1058 119,458
Salerno 1996–2009 14 1089 63,293
Sassarib 1992–2011 18 467 37,988
Siracusa 1999–2011 11 400 18,927
Sondrio 1998–2011 12 181 13,003
Trapani 2002–2009 8 429 15,591
Umbria 1994–2011 16 875 85,138
Vareseb 1976-2011 34 860 137,184
Venetob 1990–2009 20 2097 245,898
All CRs 18,909 1,655,687
Italy 59,190
a All types but skin non-melanoma
b CRs included to estimate model-based incidence and survival (47% of all
cancer cases)
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